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ARTICLE

Pharmacogenomics of Vincristine-
Induced Peripheral Neuropathy Implicates
Pharmacokinetic and Inherited Neuropathy
Genes
Galen E.B. Wright1,2, Ursula Amstutz2,3,4, Britt I. Drögemöller2,5, Joanne Shih2, Shahrad R. Rassekh2,3,
Michael R. Hayden1,2, Bruce C. Carleton2,3,†, Colin J.D. Ross2,5,† and The Canadian Pharmacogenomics
Network for Drug Safety Consortiuma
Vincristine is an effective chemotherapeutic drug for various cancers, including acute lymphoblastic leukemia (ALL).
Unfortunately, clinical utility is restricted by dose-limiting vincristine-induced peripheral neuropathies (VIPN). We
sought to determine the association of VIPN with a recently identified risk variant, CEP72 rs924607, and drug
absorption, distribution, metabolism, and excretion (ADME) gene variants in pediatric ALL. This was followed by a
meta-analysis of pharmacogenomic data from over 500 patients. CEP72 rs924607 was significantly associated with
VIPN (P = 0.02; odds ratio (OR) = 3.4). ADME analyses identified associations between VIPN and ABCC1 rs3784867
(P = 5.34 × 10−5; OR = 4.9), and SLC5A7 rs1013940 (P = 9.00 × 10−4; OR= 8.6); genes involved in vincristine
transport and inherited neuropathies, respectively. Meta-analysis identified an association with a variant related to
TTPA (rs10504361: P = 6.85 × 10−4; OR = 2.0), a heritable neuropathy-related gene. This study provides essential
corroboratory evidence for CEP72 rs924607 and highlights the importance of drug transporter and inherited
neuropathy genes in VIPN.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Dose-limiting VIPNs have been shown to have a genetic
component. Pharmacogenomic studies have begun to identify
genetic factors that can help explain these adverse reactions, but
more research is required in this regard.
WHAT QUESTION DID THIS STUDY ADDRESS?
 To assess whether the CEP72 biomarker and drug ADME
pharmacogenomic variants are associated with VIPN in pediatric patients with ALL.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 We confirmed the association of CEP72 rs924607 with
VIPN, providing additional evidence for the potential clinical
utility of this biomarker. Further, we showed that genetic
Vincristine is an antineoplastic agent that is used to treat various
cancers. This includes the most common pediatric form, acute
lymphoblastic leukemia (ALL), a cancer that has survival rates

variation within the vincristine drug transporter (ABCC1) was
also associated with VIPN. Last, we uncovered the first evidence
that genes that cause inherited neuropathies (SLC5A7 and
TTPA) may contribute to VIPN susceptibility.
HOW
MIGHT
THIS
CHANGE
CLINICAL
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 These findings will help guide the development of predictive markers and neuroprotective strategies for VIPN in order
facilitate precision medicine and optimal care on an individualized basis for oncology patients.

that have increased to over 90% in certain world regions in recent
decades.1,2 Vincristine-induced neurotoxicity is a common and severe adverse drug reaction (ADR) that can occur in over 50% of
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vincristine-treated patients.3–5 This potentially life-threatening Table 1 Clinical and demographic characteristics of the
and debilitating toxicity includes vincristine-induced peripheral CPNDS pediatric patients with ALL
neuropathy (VIPN), which can cause loss of motor function, abnorControls
Cases
(n = 57)
(n = 167)
mal sensation, and pain.6 This reaction severely affects the quality Patient
VIPN grade = 0
P value
VIPN grade ≥ 2
characteristics
of life of patients, as well as influences the dosing and clinical utility
7
4.8 (3.3–9.0)
5.4 (3.3–9.0)
0.63
of the drug. Genetic causes are thought to play an important role Age, years (median
in this ADR because VIPN-susceptibility varies across ancestries8 (IQR))
Sex (male n, (%))
101 (60.4%)
23 (40.4%)
0.009
and the trait has been shown to be heritable in model organisms.9
812
757
0.0004
Pharmacogenomics provide an attractive approach to mitigate Vincristine
(759–1137)
(745–825)
VIPN – predictive testing would allow patients to be stratified duration, days
(median (IQR))
according to risk before treatment, allowing for either increased
61.4
66.0
0.17
monitoring or dose changes in at-risk patients. Furthermore, Vincristine
cumulative dose,
(48.0–72.0)
(51.0–74.8)
the identification of genetic risk factors may provide novel in- mg/m2 (median
sights into the mechanisms underlying variability in VIPN- (IQR))
susceptibility. Recently, a genome-wide association study (GWAS) Vincristine doses,
39 (32–45)
38 (37–39)
0.47
in two cohorts reported that variation linked to the microtubule- number (median
organizing centrosomal protein, CEP72, significantly contrib- (IQR))
utes to the risk of VIPN in pediatric ALL.10 This is in line with Concomitant medication (n, (%))
the mechanism of action of vincristine, which perturbs mitosis
Strong cy59 (35.3%)
17 (29.8%)
0.52
tochrome P450
by interfering with microtubule formation.7,11 An initial replica3A inhibitorsa
tion study failed to detect a significant association between this
Antifungal azoles
54 (32.3%)
14 (24.6%)
0.32
CEP72 risk genotype and VIPN,12 which may have been driven
Nifedipine
22
(13.2%)
1
(1.8%)
0.01
by differences in the therapy stage during which VIPN was as13
sessed (i.e., continuation vs. induction). Subsequently, members Genetic ancestry (median (IQR))
of the research group involved in the discovery of the CEP72-
0.011
0.010
0.03
PC 1 (African
[0.010–0.012]
[0.008–0.012]
from
VIPN association replicated this finding in a clinical trial of adult
non-African)
patients with ALL,14 but confirmation in an independent pediatPC
2 (European
0.020
0.019
0.17
ric cohort is still warranted.
from Asian)
[0.017–0.022]
[0.011–0.021]
We, therefore, assessed the relationship between VIPN and
0.008
0.006
0.02
PC 3 (South
CEP72 genotype in a retrospective cohort of pediatric patients
[0.005–0.012]
[0.002–0.010]
Asian from
with ALL. This was followed by an exploratory analysis of pharnon-South
macogenomic variants from absorption, distribution, metabolism,
Asian)
and excretion (ADME) genes and a meta-analysis of ADME ge0.010
0.010
0.37
PC 4 (Amerindian
[0.006–0.013]
[0.005–0.012]
netic variants that overlapped variants from the previous GWAS.10
from
non-Amerindian)
Studies such as these provide essential corroboratory clinical evidence for previously identified drug safety biomarkers, while also ALL, acute lymphoblastic leukemia; CPNDS, Canadian Pharmacogenomics
Network for Drug Safety; IQR, interquartile range; PC, principal component.The
identifying additional variants for future study.
Wilcoxon rank-sum test or Fisher’s exact test where appropriate. P < 0.05
RESULTS

regarded as significant and is displayed in bold in the table.
a
Classified as inhibitors according to the Flockhart Table35

A total of 167 cases (i.e., VIPN grade ≥ 2) and 57 controls (i.e.,
VIPN grade 0) met clinical and genomic quality control and
were included in the discovery pharmacogenomic association
studies, after excluding 29 patients with grade 1 VIPN and 12
patients with only cranial or autonomic neurotoxicities (Figure S1,
Table S1). This study design is classified as a nonmatched case-
control association study, in which significantly different clinical
and demographic factors between cases and controls were corrected for during pharmacogenomic association analyses. The
majority of VIPN cases were classified as grade 2 (n = 100), followed by grade 3 (n = 66), and grade 4 (n = 1). The median days
from first vincristine dose to VIPN were 57 (interquartile range:
18–127 days). Patients were predominantly of European genetic
ancestry (78%, Figure S2) and treatment protocol information
is listed in Table S2. Table 1 depicts differences in clinical and
demographic factors between VIPN cases and controls. Cases
were more likely to be male and received vincristine for a longer

duration compared to controls (median of 812 days vs. median of
757 days). All controls, however, received vincristine for at least
16 months, a period of time in which 94% of cases had developed
VIPN (Figure S3), indicating sufficient follow-up time. The cumulative vincristine dose was not significantly associated with
case status, whereas duration of treatment was. This observation
may have resulted from the fact that many VIPN cases had either
vincristine doses held or reduced during treatment as a result of
the experienced toxicities, which may explain the difference in
therapy duration and the lack of association with cumulative dose.
Cases were also more likely to have received nifedipine compared
to controls. To help reduce the influence of potential confounders on the genetic association analyses, all significantly associated
demographic/clinical variables (i.e., sex, vincristine duration, and
nifedipine use) were included as covariates in regression models
along with genetic ancestry.
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Figure 1 CEP72 is significantly associated with vincristine-induced peripheral neuropathies (VIPN) in pediatric patients with acute
lymphoblastic leukemia. (a) Recessive genotype frequencies for CEP72 rs924607 differed significantly between VIPN cases and controls
(P = 0.02). The TT risk genotype occurred in 16.0% of cases (VIPN grade ≥2) and 5.4% of controls (VIPN grade 0). (b) Meta-analysis of the
association of CEP72 rs924607 and VIPN confirms the role of this variant with vincristine-related adverse effects. The gray summary diamond
indicates meta-analysis results including all studies, whereas the blue summary diamond shows the results for studies where VIPN was
assessed throughout continuation therapy (i.e., excluding the Gutierrez-Camino et al.12 study). Genotype 95% confidence intervals (CIs) are
represented for consistency across all studies, as opposed to the 90% CI that was used to determine CEP72 rs924607 replication evidence
for the Canadian Pharmacogenomics Network for Drug Safety cohort in the current study.10,13,14

The CEP72 rs924607 TT genotype was significantly associated with VIPN in the Canadian Pharmacogenomics Network
for Drug Safety (CPNDS) cohort (one-sided P = 0.02; odds ratio
(OR) = 3.43; 90% confidence interval (CI) = 1.15–10.3). The
TT risk genotype frequencies for CEP72 rs924607 were 16.0% in
VIPN cases and 5.4% in controls (Figure 1a, Table S3), displaying a specificity of 0.95 (95% CI = 0.85–0.99) and sensitivity of
0.16 (95% CI = 0.11–0.22). The association between the CEP72
rs924607-TT genotype and VIPN was further confirmed in a
meta-analysis of the CPNDS results and published-CEP72-VIPN
studies (Figure 1b; n studies = 4; P = 8.02 × 10−11; OR = 2.77;
95% CI = 2.04–3.76; no heterogeneity: I2 = 0.0%).
Subsequent analysis of 4,522 ADME variants meeting the inclusion criteria for association testing revealed that no other previously identified variant was significantly associated with VIPN
(i.e., P < 0.05; Table S4). Further, no variants assessed within
the vincristine metabolism-related gene cluster (i.e., CYP3A5-
CYP3A7-CYP3A4) displayed P < 0.05. An intronic ABCC1
polymorphism (Table S5) was the top ADME variant with the
404

strongest evidence of association (rs3784867 P = 5.34 × 10−5;
OR = 4.91; 95% CI = 1.99–12.10; specificity = 0.88; sensitivity
= 0.36; Table S6). The frequency of rs3784867 genotypes correlated with VIPN grade upon the inclusion of grade 1 patients
(Figure 2a; P = 7.12 × 10−4). We assessed ABCC1 rs3784867 for
replication in the previously published VIPN-GWAS summary
statistics,10 and, although the risk allele was more frequent in cases
in both the St Jude Total XIIIB and COG AALL0433, only suggestive evidence for replication in the combined XIIIB-COG cohorts was observed (one-sided P = 0.08). Interestingly, the third
most significant finding from the ADME analyses was a missense
variant in SLC5A7 (rs1013940 P = 9.00 × 10−4; OR = 8.60; 95%
CI = 1.68–44.15; specificity = 0.96; sensitivity = 0.18; Table S7),
a gene that encodes a choline transporter, where mutations are
known to cause a form of hereditary motor neuropathy.15 Of
note, all homozygous risk variant carriers presented with the most
severe VIPN grade (Figure 2b). This variant is also an SLC5A7
expression quantitative trait locus (eQTL and Genotype-Tissue
Expression (GTEx) multitissue P = 3.62 × 10−7).16 Unfortunately,
VOLUME 105 NUMBER 2 | FEBRUARY 2019 | www.cpt-journal.com
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Figure 2 Top absorption, distribution, metabolism, and excretion (ADME)-vincristine-induced peripheral neuropathies (VIPN) variant genotypes
stratified by severity of the adverse event. (a) ABCC1 rs3784867 was the most significantly associated pharmacogenomic variant in the
VIPN-ADME analyses (P = 5.34 × 10 −5; odds ratio (OR) = 4.9). Genotype frequency was also correlated with severity of the adverse event
(P = 7.12 × 10 −4). (b) SLC5A7 rs1013940 is a missense variant in a peripheral neuropathy gene that was among the most significantly
associated ADME variants (P = 9.00 × 10 −4; OR = 8.6). The variant was also moderately associated with VIPN grade severity (P = 0.01),
with all homozygous carriers of the risk allele presenting with severe VIPN (i.e., grade 3 and 4). Because only one case of grade 4 VIPN was
observed in this cohort, this patient was combined with the grade 3 group.

no data were available for this variant or those in linkage disequilibrium in the GWAS summary statistics, so we were unable to assess the SLC5A7 variant for replication or in the meta-analysis.
We performed annotation of the ABCC1 rs3784867 variant to
delineate its potential functional role. No variants in strong LD
(i.e., r2 > 0.8 and no missense variants with D′ > 0.8) with the
marker were identified in the 1,000 Genomes Project. Annotation
of rs3784867 with DNAse and histone ChIP-Seq data indicated
the presence of enhancer and histone marks in five tissues/cell types
(i.e., embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, smooth muscle, and the pancreas). Additionally,
rs3784867 was predicted to alter homeobox transcription factor
motifs (Figure S4).
The most significant association detected in the VIPN-ADME-
GWAS meta-analysis (Table S8) of 379 variants was rs10504361

(P = 6.85 × 10−4; OR = 1.98; 95% CI = 1.34–2.94; Figure 3).
This variant is a GTEx-eQTL16 for the TTPA and GGH genes.
Because TTPA mutations are known to cause ataxia with isolated
vitamin E deficiency, a neurologic condition associated with neuropathies,17 we assessed differences in predicted gene expression of
TTPA in the tibial nerve with S-PrediXcan, which collapses eQTL
data by gene, in the GWAS-array genotyped cohorts. These analyses revealed positive gene-level Z-scores in both cohorts, indicating
that VIPN cases were predicted to have increased expression compared to controls (P = 6.1 × 10−5).
DISCUSSION

Pediatric oncology has seen a dramatic improvement in the prognosis for patients over recent decades, yet ADRs from these drugs
have become an increasing concern. In this study, we independently
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(a)

The most significant result from CPNDS/TXIIIB/COG meta-analysis (rs10504361)

P-value = 6.9 x 10-4

(b)

The variant is an eQTL for
TTPA in the tibial nerve

(c)

Rank normalized gene expression

2

1

0

Predicted TTPA gene expression is
significantly different between cases
and controls (S-PrediXcan)

Gene

Tissue

Cohort

TTPA

Tibial
nerve

Total XIIIB
COG

Z-score P-value
2.79
3.88

0.04
0.0001

Meta-analysis P-value = 6.1 x 10-5

-1

P = 2.3 x 10-4
Effect size = 0.32

-2
Homo Ref
N = 289

Het
N = 66

Homo Alt
N=6

Figure 3 Association of TTPA-related variation and gene expression with vincristine-induced peripheral neuropathy (VIPN). (a) Meta-analysis
of overlapping absorption, distribution, metabolism, and excretion (ADME)-genomewide association study (GWAS) variants in the Canadian
Pharmacogenomics Network for Drug Safety (CPNDS)/St Jude Total XIIIB/COG AALL0433 cohorts identified rs10504361 as the most
significantly associated variant. (b) This variant has been shown to be associated with differential expression of the TTPA gene in the tibial
nerve in GTEx. (c) Imputing expression of TTPA using genome wide array data revealed that VIPN cases were predicted to have higher levels of
TTPA expression compared to controls as reflected by gene-level S-PrediXcan Z-scores (i.e., positive scores indicate increased expression is
associated with increased risk for VIPN). CI, confidence interval; OR, odds ratio.

confirmed a role of CEP72 rs924607 in VIPN susceptibility for
the first time in a retrospective cohort of pediatric patients. This
finding validates the importance of this pharmacogenomic variant for the prediction of a serious ADR caused by an essential chemotherapeutic agent. Our exploratory pharmacogenomic analyses
also brought to light the potential VIPN-related importance of
the transporter, ABCC1, and highlighted genes associated with
inherited neuropathy conditions, such as SLC5A7 and TTPA.
Confirmation of CEP72 as a pharmacogenomic risk factor
for VIPN

CEP72 rs924607 is a promising VIPN biomarker given its potential role in the mechanism of action of this antimitotic agent.
However, prior to the current study, all evidence supporting this
finding was obtained from a single research group, although for
the most recent replication study,14 these investigators collaborated on the study by performing genotyping of CEP72 rs924607
while blinded to VIPN phenotype. Of note, this the only other external study refuting the role of this variant in VIPN. Our positive
results, supported by a meta-analysis of published VIPN-CEP72
studies,10,12,14 provide the first external validation of this finding
in pediatric patients. In particular, the replication of CEP72 in
a diverse pediatric ALL cohort confirms the generalizability of
this pharmacogenomic marker. Our data also improve the precision and accuracy of estimates regarding the effect of this variant
(meta-analysis: P = 8.02 × 10−11; OR = 2.77; 95% CI = 2.04–
3.76) in studies assessing VIPN from vincristine continuation
406

therapies. Concurrently, these results corroborate the validity of
our grading scheme that retrospectively assessed VIPN based on
medical records of patients recruited via active surveillance.
The failure of the first rs924607-VIPN replication attempt12
brings to light important phenotypic considerations for pharmacogenomic studies. Unlike the discovery study, which included
monitoring during induction and continuation phases of vincristine therapy, Gutierrez-Camino et al.12 assessed VIPN solely
during the 4-week induction phase of vincristine therapy. Of note,
the majority (63%) of the VIPN cases in our cohort developed toxicity after this 4-week time frame (Figure S3). Our meta-analysis
was highly significant when excluding this study12 assessing VIPN
only during induction therapy from analysis with no evidence for
heterogeneity between studies. It has further been suggested that
CEP72 rs924607 may be primarily relevant to patients receiving
vincristine doses of <2 mg/m2 because higher doses of vincristine may overcome the protective influence of the ancestral genotypes.13 Indeed, when excluding the CPNDS patients that received
vincristine doses ≥ 2 mg/m2 (i.e., 34.3% of the cohort), the risk
genotype was carried exclusively in cases (i.e., 16.1% of 112 cases;
Fisher’s exact P = 0.007). These findings emphasize the importance of carefully matching drug-induced phenotypes in pharmacogenomic replication studies.18
Exploratory analyses of ADME genetic variation

Because numerous pharmacogenes belong to ADME-
related
pathways,19 we conducted an exploratory association analysis of
VOLUME 105 NUMBER 2 | FEBRUARY 2019 | www.cpt-journal.com
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ADME variants with regards to VIPN using a custom genotyping panel that extensively captures variation within these regions.
Initial pharmacogenomic studies investigating VIPN hypothesized that CYP3A genetic variation may be relevant for this ADR
because vincristine is chiefly metabolized by these enzymes.8 Our
results, however, indicate that pharmacogenomic variation in
CYP3A genes did not contribute significantly toward this phenotype in our patient cohort.
Our analyses revealed that the ADME variant with the
strongest evidence for an association with VIPN, rs3784867
(P = 5.34 × 10−5; OR = 4.91; 95% CI = 1.99–12.10), occurs in
the intron of ABCC1. This gene encodes multidrug resistance
protein 1, a protein, which is involved in both transport of, and
resistance to, vincristine.20,21 ABCC1 has also been implicated
in anthracycline-
related and methotrexate-
related pharmacogenomic phenotypes.22 Rs3784867 is predicted to alter binding
sites for homeobox transcription factors (Figure S4), which are
involved in hematopoiesis and are dysregulated in leukemia,23
indicating that rs3784867 could affect the expression of ABCC1.
Notably, previous pharmacogenomic studies have detected associations with ABCC1 and the paralogous transporter ABCC2 and
VIPN-risk,24,25 although we did not replicate associations of the
variants that were implicated in these studies. As discussed previously, heterogeneity in VIPN assessment may contribute toward
the lack of transferability of pharmacogenomic markers between
studies and because our study used an intervention-based VIPN
grading scheme, this may have contributed toward these discrepant results. The correlation between rs3784867 and ADR severity
adds support for this variant’s role in VIPN risk. However, because
only suggestive evidence for replication was observed in the GWAS
summary statistics for rs3784867, it is, important to further investigate this variant in additional VIPN cohorts.
Overlap between the genomics of VIPN and inherited
neuropathy conditions

It has been suggested that a continuum exists between the genetic
etiology of Mendelian disorders and drug-induced traits that present with similar clinical phenotypes.26 This is in line with what
has been observed for GWAS of chemotherapy-induced peripheral neuropathies from paclitaxel (FGD4 gene)27 and docetaxel
(VAC14 gene), 28 whereas both genes have also been implicated
in inherited neuropathy conditions. Phenotype overlaps are further substantiated by the fact that vincristine is contraindicated
in patients with hereditary neuropathies (e.g., Charcot-Marie-
Tooth disease), because VIPN can be particularly severe in these
patients.29 Our VIPN-A DME-GWAS meta-analysis identified
a variant (rs10504361) that is associated with the expression
of TTPA in the peripheral nervous system. This protein influences bioavailability of alpha-tocopherol, a form of vitamin E.
Deleterious TTPA mutations cause the recessive neurodegenerative condition ataxia with isolated vitamin E deficiency, which is
associated with peripheral neuropathy.30 In silico gene expression
analysis indicated that cases were predicted to have increased levels of TTPA in the tibial nerve when compared to controls. This
finding warrants further research to delineate the potential mechanism of action of the variant in the context of VIPN. Sensory

conduction in the tibial nerve has been shown to be impaired in
vincristine treated patients with ALL31 and it has motor functions
through innervating the muscles of the leg, including the tibialis
posterior muscle, which is involved in plantar flexion.32 This indicates that the tibial nerve may be an appropriate model to study
gene expression in VIPN. Finally, our third most highly associated
VIPN-A DME gene was SLC5A7, a choline transporter that is implicated in distal hereditary motor neuropathy type 7A 15 and congenital myasthenic syndromes, which are associated with muscle
weakness.33 Given that the association with VIPN was observed
for a missense SLC5A7 variant (rs1013940) with a large effect
size (OR > 8), and the similarity of the ADR and inherited phenotypes related to this gene, this candidate variant also warrants
further investigation.
Context of current VIPN pharmacogenomic findings

With the availability of high throughput genotyping platforms,
pharmacogenomic studies are beginning to uncover novel biology
that contributes toward ADRs in a clinically relevant manner.19
Although the current investigation provides valuable findings,
there are caveats. Despite the fact that the sample size of the current study is relatively large for a pharmacogenomic study, including more patients in future cohorts would be beneficial. This is
reflected by the fact that our exploratory analysis of ADME variants yielded no associations reaching statistical significance after
stringent Bonferroni multiple testing correction. Additional confirmatory evidence should also be pursued in the future through
functional experiments for the novel candidate genes identified
in the ADME/GWAS analyses. Nonetheless, given the known
involvement of the highlighted genes in vincristine pharmacokinetics and inherited neuropathy conditions, this study provides
interesting avenues for future research. The retrospective nature
of this study is also a potential limitation, because milder forms
of VIPN may be poorly captured in standard medical records.
We took great care in developing a slightly augmented Common
Terminology Criteria for Adverse Events (CTCAE) grading
scheme that can be applied in this context. Indeed, our results
support the appropriateness of this grading scheme through the:
(i) replication of the VIPN CEP72 GWAS variant with a similar
effect size as previously reported; (ii) identification of candidate
genes that have a clear biological mechanism pertaining to the
ADR; and (iii) the correlation of the genotype frequencies of top
candidate variants with VIPN severity.
Conclusions and future directions

VIPNs are important clinical concerns, especially given the increased survival rates of pediatric patients with cancer and potential long-term effects of this ADR. The confirmatory results
obtained in the current study highlight the CEP72 rs924607 risk
marker for further evaluation of its clinical utility in the context
of potential pharmacogenomic risk predictions and preventive interventions. Specifically, predicting in whom debilitating VIPN
is likely to occur would allow clinicians to discuss other therapeutic options, additional physiotherapy interventions, and, importantly, inform patients and parents in advance what toxicity may
occur, further enhancing the family’s role in cancer management.
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Given the current level of evidence for the CEP72 risk genotype, increased clinical monitoring and earlier initiation of
physiotherapy interventions for VIPN in rs924607 TT patients
could potentially be beneficial. Oncologists may also consider
ALL treatment protocols with lower doses of vincristine and/or
shorter vincristine treatment durations in high-risk genotypes. It
is important to note that alternative protocols should fall within
current standards of care and display similar efficacy and survival
outcomes. The results of an ongoing clinical trial investigating the
influence of vincristine dose and duration reductions in CEP72
rs924607 TT patients (ClinicalTrials.gov: NCT03117751) will
also be highly informative in determining whether pharmacogenomic genotyping can minimize VIPN risk while maintaining
treatment efficacy.
Additional VIPN pharmacogenomic markers, if confirmed
through future replication, may further improve VIPN risk stratification. Finally, it will also be beneficial for future studies to use
high-throughput sequencing approaches to delineate extreme cases
of VIPN in future studies, given the importance of rare variation
for pharmacogenomic traits.19 In particular, resequencing studies
would enable the investigation of rare variants in candidate genes
for VIPN, such as the ones identified in this study. Comprehensive
risk assessments that take different clinical, demographic, and
pharmacogenomic factors into account may, therefore, ultimately
lead to safer and more effective use of vincristine-based chemotherapy in children.
METHODS
Patients and clinical assessment
Pediatric patients with ALL (age at diagnosis ≤18 years) receiving
treatment protocols, including vincristine, were recruited from seven
pediatric hospitals across Canada (Calgary, London, Ottawa, Montréal,
Toronto, Vancouver, and Winnipeg). Written informed consent and/or
assent was obtained from all participants or their parents/legal guardians.
The study was approved by ethics committees at participating universities
and hospitals. Relevant clinical and demographic data were collected
using the CPNDS active surveillance methodology.34 This included
capturing information for relevant concomitant medications (e.g., CYP3A
inhibitors, because these enzymes represent the major metabolic path of
vincristine).7,35
Patients were assessed for vincristine-
related neurotoxicities using
a refined National Cancer Institute (NCI) CTCAE version 4.0
Grading System (Table S1). Specifically, to facilitate grading of the
retrospective clinical data and standardize grading across multiple sites,
this system included definitions of neurotoxicity-related clinically based
interventions, such as pharmacotherapy, rehabilitative therapy, and
vincristine dose reductions, to complement the relatively broad definitions
(e.g., “noninvasive intervention” or “limiting activities of daily living”)
used in the CTCAE. To be considered for grading, any intervention
had to be used specifically for the treatment for vincristine-
related
neurotoxicities, and any symptom had to be attributed to vincristine-
related neurotoxicities. We excluded patients with grade one (minor)
VIPN from our initial pharmacogenomic nonmatched case-
control
association analyses (Figure S1, cases were defined as grade ≥2, whereas
controls were defined as patients not developing neuropathy, referred to
as grade 0), because the need for a predictive biomarker is greater in those
patients with neurotoxicity of sufficient severity to warrant a modification
in clinical care (increased monitoring and drug therapy changes). In
addition, patients presenting only with symptoms of cranial or central
nervous system neurotoxicities without motor or sensory neurotoxicity
were not included in the analysis.
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Pharmacogenomic genotyping and quality control
Genomic DNA from participants was genotyped for CEP72 rs924607
using a TaqMan assay (C___8292459_20; ThermoFisher, Waltham,
MA) and for 7,907 ADME variants with a custom Infinium Panel
(Illumina, San Diego, CA).36 ADME genotype clusters were extracted
from GenomeStudio Software (Illumina) and underwent standard
quality control procedures. Specifically, array data were assessed for
variant (≥95%) and sample call rates (≥90%), and deviations from Hardy
Weinberg equilibrium (Fisher’s exact P < 0.001 in controls).
Bioinformatic and statistical analyses
Statistical and bioinformatic analyses were performed using either R or
SNP & Variation Suite (SVS) version 8.4 (Golden Helix, Bozeman, MT),
unless otherwise stated. Genetic ancestry was determined via principal
component analyses using pruned ADME genotypes (50-variant window,
shifted by 5-variants after each assessment, pruning r2 > 0.5) and minor
allele frequency <0.01 with EIGENSOFT version 5.0, incorporating the
1,000 Genomes Project37 samples as a reference. The first four principal
components, along with clinical factors that differed significantly (P < 0.05)
between cases and controls were included in subsequent case-control
association analyses to correct for possible population stratification and
clinical confounders. Sensitivity and specificity of prioritized variants were
calculated with epiR (https://cran.r-project.org/web/packages/epiR).
To investigate the CEP72 rs924607 VIPN risk genotype, we decided a
priori to first test for an association between this marker and VIPN using
a recessive model, as reported in the initial study. For this analysis, a one-
sided P value < 0.05 was considered statistically significant. A random-
effects meta-analysis was performed on CEP72 rs924607, incorporating
the results from this study along with published data, using the GWAMA
software38; related plots were generated in the R package, forestplot
(https://CRAN.R-project.org/package=forestplot).
These analyses were followed by exploratory association analyses of
ADME variants passing quality control, and displaying minor allele
frequency >0.05, using logistic regression and an additive genetic model.
Due to the exploratory nature of this analysis, multiple testing corrections
using a conservative Bonferroni threshold was not applied. Instead, variants
with P < 0.001 were prioritized. To provide corroboratory evidence for
top VIPN-associated variants, ordinal regression of VIPN grade was also
performed using the R package ordinal.
An Embase literature search (further details are provided in Table S4)
was completed to identify previously identified VIPN-related variants and
assess their association with the ADR in the CPNDS cohort. Further,
VIPN-GWAS summary statistics were obtained for the two pediatric
ALL cohorts from Diouf et al.10 and a meta-analysis of nonambiguous
overlapping ADME variants with evidence for association (P < 0.05) in at
least one cohort was performed as specified above.
To examine predicted functional effects of variants prioritized from
the association analyses, Ensembl Variant Effect Predictor,39 HaploReg
version 4.1,40 GTEx,16 and the JASPAR Core Database41 were used to
annotate variants. Differences in predicted gene expression profiles in
the tibial nerve16 between GWAS-genotyped VIPN cases and controls
were calculated using S-PrediXcan,42 where specified, with P values being
combined using Fisher’s method in metap (https://cran.r-project.org/web/
packages/metap).

S U P P O R T I N G I N F O R M AT I O N
Supplementary information accompanies this paper on the Clinical
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. CONSORT diagram of pediatric ALL patients included in the
CPNDS VIPN study.
Figure S2. Principal component analysis of the CPNDS VIPN cohort
(cases, n = 167; controls, n = 57; grade 1 VIPN, n = 29), including
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the Phase 3 1,000 Genomes Project samples as a reference (AMR,
Admixed American; AFR, African; EAS, East Asian; EUR, European;
SAS, South Asian).

M.R.H., B.C.C., and C.J.D.R. performed the research. G.E.B.W., U.A.,
B.I.D, B.C.C., and C.J.D.R. analyzed the data.

Figure S3. Cumulative percentage of vincristine-induced peripheral
neuropathy cases over time, indicating that 94% of cases developed
in the first 16 months after initiating vincristine therapy (blue dashed
line).
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Figure S4. Human transcription factor binding site analysis of the
ABCC1 rs3784867 variant (C>T).
Table S1. Refined CTCAE vincristine-
induced neurotoxicity grading
scale that specifies clinical interventions related to neurotoxicity.
Table S2. Summary of the treatment protocols for the CPNDS pediatric ALL cohort included in the pharmacogenomic association analyses.
Table S3. CEP72 rs924607 genotype counts in pediatric patients with
ALL stratified by VIPN status.
Table S4. Literature search strategy for identification of previously
identified VIPN pharmacogenomic variants and assessment of these
variants in the CPNDS ALL cohort.
Table S5. Top ADME variants associated with VIPN (P < 0.001) in the
pediatric CPNDS ALL cohort.
Table S6. ABCC1 rs3784867 genotype counts in pediatric patients
with ALL stratified by VIPN status.
Table S7. SLC5A7 rs1013940 genotype counts in pediatric patients
with ALL stratified by VIPN status.
Table S8. Most significant associations from the VIPN-ADME-GWAS
meta-analysis of the St Jude Total XIIIB, COG AALL0433, and CPNDS
cohorts.
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